Document:

EX-10.3 Agreement for Member of the Scientific Advisory Committee, Joel L. Zive

 

 

AGREEMENT FOR MEMBER OF THE SCIENTIFIC ADVISORY COMMITTEE

 

 

       
THIS AGREEMENT is made and entered into effective as of July 7, , 2009 (the
"Effective Date"), by and between Immunotech Laboratories Inc., a Nevada
corporation, ("Company") and Joel L. Zive an individual ("Advisor").

 

       
1. Term.

 

(a)
This Agreement shall continue for a period of one (3) years from the Effective
Date and shall continue thereafter for as long as Advisor is requested to
remain on the Scientific Advisory Board of the Company.

 

b)
Notwithstanding the foregoing and provided that Advisor has neither voluntarily
resigned nor been terminated for "cause" as defined in Section 3(b)
of this Agreement, Company agrees to use its best efforts to reappoint Advisor
to the Scientific Advisory Board.

 

       
2. Position and Responsibilities.

 

(a)
Position. Company hereby retains Advisor to serve as member of the Scientific
Advisory Committee. Advisor shall perform such duties and responsibilities as
are normally related to such position in accordance with Company's bylaws and
applicable law, including those services described on Exhibit A, (the
"Services"), and Advisor hereby agrees to use his best efforts to
provide the Services. Advisor shall not allow any other person or entity to perform
any of the Services for or instead of Advisor. Advisor shall comply with the
statutes, rules, regulations and orders of any governmental or

quasi-governmental
authority, which are applicable to the performance of the Services, and
Company's rules, regulations, and practices as they may from time-to-time be
adopted or modified.

 

 

 

(b)
Other Activities. Advisor may be employed by another company, may serve on
other Scientific Advisory Committees or Advisory Boards, and may engage in any
other business activity (whether or not pursued for pecuniary advantage), as
long as such outside activities do not violate Advisor's obligations under this
Agreement or Advisor's obligations to the Company. 

The
ownership of less than a 5% interest in an entity, by itself, shall not
constitute a violation of this duty.

Advisor
represents that, to the best of his/her knowledge, Advisor has no outstanding
agreement or obligation that is in conflict with any of the provisions of this
Agreement, and Advisor agrees to use his/her best efforts to avoid or minimize
any such conflict and agrees not to enter into any agreement or obligation that
could create such a conflict, without the approval of the Company. If, at any
time, Advisor is required to make any disclosure or take any action that may
conflict with any of the provisions of this Agreement, Advisor will promptly
notify the Company of such obligation, prior to making such disclosure or
taking such action.

 

(c)
No Conflict. Except as set forth in Section 2(b) and Exhibit A, Advisor will
not engage in any activity that creates an actual conflict of interest with
Company, regardless of whether such activity is prohibited by Company's
conflict of interest guidelines or this Agreement, and Advisor agrees to notify
the Company before engaging in any activity that creates a potential conflict
of interest with Company. Specifically and except as set forth in Section 2(b)
and Exhibit A of this Agreement, Advisor shall not engage in any activity that
is in direct competition with the Company or serve in any capacity (including,
but not limited to, as an employee, consultant, advisor or director) in any
company or entity that competes directly with the Company, as reasonably
determined by the Company, without the approval of the Company.

 

 

 

 

 

       
3. Compensation and Benefits.

 

(a)
Stock and Stock Options. Company acknowledges that in consideration of the
services to be rendered under this Agreement, Company agrees to grant Advisor
the following:

For
each year of services rendered, 25,000 shares of the company's common stock,
for a total of 75,000 common shares.   The first year 25,000 shares are given
to the Advisor up front.  Upon the effective date of this agreement, the
company will process the initial 25,000 rule 144 restricted shares, which shall
be fully vested six months from the Effective Date.  The remaining 50,000
shares will be given to the advisor as follows:  25,000 shares at the end of
year two and 25,000 shares at the end of year three.  In the event (i) of a
merger, change in control or sale of Company or (ii) Advisor either is
terminated as an Advisor or is not reappointed, where the Advisor has not
engaged in conduct during his tenure on the board which would constitute
"cause" for such termination, as determined by the Company, the
Shares immediately shall become fully vested. "Cause" means a determination
by Company that the Advisor has been engaged in any of the following: (i)
malfeasance in office; (ii) gross misconduct or neglect; (iii) false or
fraudulent misrepresentation inducing Advisor's appointment; (iv) willful
conversion of corporate funds; (v) material breach of an obligation to make
full disclosure; (vi) gross incompetence; (vii) gross inefficiency; (viii) acts
of moral turpitude; or (ix) repeated failure to participate in agreed upon
scientific or trade conferences, scientific and technical meetings or
teleconferences despite having received proper notice of such at least 48 hours
in advance thereof. 

 

(b)
Expenses. The Company shall reimburse Advisor for all approved reasonable
business expenses incurred in the performance of his/her duties hereunder in
accordance with Company's expense reimbursement guidelines.

 

(c)
Indemnification. Company will indemnify and defend Advisor  against any
liability incurred in the performance of the Services to the fullest extent
authorized in Company's Certificate of Incorporation, as amended, bylaws, as
amended, and applicable law. Advisor shall be entitled to the protection of any
insurance policies the Company maintains for the benefit of the Company against
all costs, charges and expenses in connection with any action, suit or
proceeding to which he may be made a party by reason of his affiliation with
Company, its subsidiaries, or affiliates.

 

(d)
Records. Advisor shall have reasonable access to scientific and technical
information and data of Company, as necessary to enable Advisor to fulfill his/her
obligations as an Advisor of Company.

 

       
4. Termination.

 

a)
Right to Terminate. At any time, Advisor may be removed as provided in
Company's Certificate of Incorporation, as amended, bylaws, as amended, and
applicable law. Advisor may resign as Advisor as provided in Company's
Certificate of Incorporation, as amended, bylaws, as amended, and applicable
law. Notwithstanding anything to the contrary contained in or arising from this
Agreement or any statements, policies, or practices of Company, neither Advisor
nor Company shall be required to provide any advance notice or any reason or
cause for termination of Advisor's status, except as provided in Company's
Certificate of Incorporation, as amended, Company's bylaws, as amended, and
applicable law.

 

b)
Effect of Termination as Advisor. Upon a termination of Advisor's status, this
Agreement will terminate. Except as provided herein, the Company shall pay to Advisor
all compensation and benefits to which Advisor is entitled up through the date
of termination, and thereafter, all of the Company's obligations under this
Agreement shall cease, except as provided in Sections 1(b), 3(b), 3(d), 3(e), and
5.

 

c)
Effect of Termination as Advisor. Upon a termination of

Advisor's
status as an Advisor, this Agreement will terminate; Company shall pay to Advisor
all compensation and benefits to which Advisor is entitled up through the date
of termination. Thereafter, all of Company's obligations under this Agreement
shall 

cease,
except as provided in Sections 1(b), 3(a), 3(b), 3(c) and 5.

 

       
5. Termination Obligations.

 

(a)
Advisor agrees that all property, including, without limitation, all equipment,
tangible proprietary information, documents, records, notes, contracts, and
computer-generated materials provided to or prepared by Advisor incident to his
services belong to Company and shall be promptly returned at the request of
Company.

 

(b)
Upon termination of this Agreement, Advisor shall be deemed to have resigned
from all offices then held with Company by virtue of his/her position as Advisor,
except that Advisor shall continue to serve as an Advisor if reappointed as an Advisor
by the Company as provided in Company's Certificate of Incorporation, as
amended, Company's bylaws, as amended, and applicable law. Advisor agrees that
following any termination of this Agreement, he/she shall cooperate with
Company in the winding up or transferring to other Advisors of any pending work
and shall also cooperate with Company (to the extent allowed by law, and at
Company's expense) in the defense of any action brought by any third party
against Company that relates to the Services.

 

(c)
The Company and Advisor agree that their obligations under this Section, as
well as Sections 1(b), 3(a), 3(b), 3(c), 4(b), 4(c) and 7, shall survive the
termination of this Agreement.

 

6. Nondisclosure Obligations. 

 

Advisor
shall maintain in confidence and shall not, directly or indirectly, disclose or
use, either during or after the term of this Agreement, any Proprietary
Information (as defined below), confidential information, or trade secrets
belonging to Company, whether or not it is in written or permanent form, except
to the extent necessary to perform the Services, as required by a lawful
government order or subpoena, or as authorized in writing by Company. These
nondisclosure obligations also apply to Proprietary Information belonging to
customers and suppliers of Company, and other third parties, learned by Advisor
as a result of performing the Services.

 

"Proprietary
Information" means all information pertaining in any manner to the
business of Company, unless (i) the information is or becomes publicly known
through lawful means; (ii) the information was part of Advisor's general knowledge
prior to his/her relationship with Company; or (iii) the information is
disclosed to Advisor without restriction by a third party who rightfully
possesses the information and did not learn of it from Company.

 

       
7. Dispute Resolution.

 

(a)
Jurisdiction and Venue. The parties agree that any suit, action, or proceeding
between Advisor (and his attorneys, successors, and assigns) and Company (and
its affiliates, shareholders, directors, officers, employees, members, agents,
successors, attorneys, and assigns) relating to the Services or the termination
of those Services shall be brought in either the United States District Court
for the Central District of California or in a California state court in the
County of Los Angeles Central District and that the parties shall submit to the
jurisdiction of such court. The parties irrevocably waive, to the fullest
extent permitted by law, any objection the party may have to the laying of
venue for any such suit, action or proceeding brought in such court. If any one
or more provisions of this Section shall for any reason be held invalid or
unenforceable, it is the specific intent of the parties that such provisions shall
be modified to the minimum extent necessary to make it or its application valid
and enforceable.

 

(b)
Attorneys' Fees. Should any litigation, arbitration or other proceeding be
commenced between the parties concerning the rights or obligations of the
parties under this Agreement, the party prevailing in such proceeding shall be
entitled, in addition to such other relief as may be granted, to a reasonable
sum as and for its attorneys' fees in such proceeding. This amount shall be determined
by the court in such proceeding. In addition to any amount received as
attorneys' fees, the prevailing party also shall be entitled to receive from
the party held to be liable, an amount equal to the attorneys' fees and costs
incurred in enforcing any judgment against 

such
party. This Section is severable from the other provisions of this Agreement
and survives any judgment and is not deemed merged into any judgment.

 

       
8. Entire Agreement. This Agreement is intended to be the final, complete, and
exclusive statement of the terms of Advisor's relationship solely with respect
to his position as Advisor with Company. This Agreement entirely supersedes and
may not be contradicted by evidence of any prior or contemporaneous statements
or agreements pertaining to Advisor's position. Agreements related to Advisor's
ownership of the Securities are not affected by this Agreement.

 

       
9. Amendments; Waivers. This Agreement may not be amended except by a writing
signed by Advisor and by a duly authorized representative of the Company other
than Advisor. Failure to exercise any right under this Agreement shall not
constitute a waiver of such right.

 

       
10. Assignment. Advisor agrees that Advisor will not assign any rights or
obligations under this Agreement, with the exception of Advisor's ability to
assign rights with respect to the Securities. Nothing in this Agreement shall
prevent the consolidation, merger or sale of Company or a sale of all or
substantially all of its assets.

 

       
11. Severability. If any provision of this Agreement shall be held by a court
or arbitrator to be invalid, unenforceable, or void, such provision shall be
enforced to fullest extent permitted by law, and the remainder of this
Agreement shall remain in full force and effect. In the event that the time
period or scope of any provision is declared by a court or arbitrator of
competent jurisdiction to exceed the maximum time period or scope that such
court or arbitrator deems enforceable, then such court or arbitrator shall
reduce the time period or scope to the maximum time period or scope permitted
by law.

 

 

       
12. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of California.

 

       
13. Interpretation. This Agreement shall be construed as a whole, according to
its fair meaning, and not in favor of or against any party. Captions are used
for reference purposes only and should be ignored in the interpretation of the
Agreement.

 

       
14. Binding Agreement. Each party represents and warrants to the other that the
person(s) signing this Agreement below has authority to bind the party to this
Agreement and that this Agreement will legally bind both Company and Advisor.
This Agreement will be binding upon and benefit the parties and their heirs,
administrators, executors, successors and permitted assigns. To the extent that
the practices, policies, or procedures of Company, now or in the future, are
inconsistent with the terms of this Agreement, the provisions of this Agreement
shall control. Any subsequent change in Advisor's duties or compensation not
affect the validity or scope of the remainder of this Agreement.

 

       
15. Advisor Acknowledgment. Advisor acknowledges Advisor has had the
opportunity to consult legal counsel concerning this Agreement, that Advisor
has read and understands the Agreement, that Advisor is fully aware of its
legal effect, and that Advsior has entered into it freely based on his own
judgment and not on any representations or promises other than those contained in
this Agreement.

 

       
16. Counterparts. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

 

 

 

 

 

 

 

 

 

 

       
17. Date of Agreement. The parties have duly executed this Agreement as of the
date first written above.

 

 

   
Immunotech Laboratories Inc.

   
a California corporation:

 

   
By: /s/ Ara Ghanime                       /s/ Harry H. Zhabilov

 

 

 

 

  
____________________                          _____________________                       

 

 

 

 

 

  
Advisor of Immunotech 

 

 

 

 

   
__________________

   
/s/  Joel L. Zive

 

 

 

                      

 

 EXHIBIT A

                         DESCRIPTION OF SERVICES

 

       
Responsibilities as Advisor. Advisor shall have all responsibilities of an Advisor
of the Company imposed by California or applicable law, the Certificate of
Incorporation, as amended, and Bylaws, as amended, of Company. These
responsibilities shall include, but shall not be limited to, the following:

 

1.     
Attendance to conferences. to be agreed upon on a case by case basis, taking
Into consideration additional compensation requirements covering time and
material;

 

2.     
Act as a Scientific/Technical Advisor. Represent the interests of Company in
all scientific, technical and business conferences and meetings,
teleconferences and conduct presentations; and

 

3.     
Assist company in its efforts to raise private, institutional and governmental
investments and grants.

 

4.      Advise
company for all scientific and technical issues and requirements in the process
of taking Company's Inactivated Pepsin Fraction technology platform from
pre-clinical studies, through the regulatory steps of all clinical trials.EX-10.4 White Coat Strategies LLC Agency Agreement

[WHITECOAT
LOGO]

 

 

 

908 Pennsylvania Ave. SE, Suite B1

Washington, DC 20003

202 547-2880

 

 

AGENCY AGREEMENT

 

This Agreement is made this 6th day of July, 2009,
between WHITECOAT LLC, a Washington, DC company ("Agency") with
offices at 908 Pennsylvania Ave. SE, Washington, DC and Immunotech Labs with
offices in 116 W. Stocker Street, Glendale, California (“Client"). 
The parties agree as follows:

 

1.   Agency shall study Client's products, markets, policies
and objectives, and communicate opportunities for public relations or publicity
programs to Client.  At Client's request, Agency shall plan, develop and
execute public relations and publicity plans and programs and before the
release of any materials, Agency shall submit materials to Client for prior
approval.

 

2. (a) Agency and Client
agree to a “retainer” based on the following breakdown:

Upon
signing of the contract Agency will have the option of acquiring thirty three
thousand (33,000) rule 144 restricted shares at fifty (50) cents a share.

After
three (3) months from signing the contract Agency will have the option of
acquiring thirty three thousand rule 144 restricted shares (33,000) at fifty (50) cents a share.

After
three (6) months from signing the contract Agency will have the option of
acquiring thirty four thousand rule 144 restricted shares (34,000) at fifty (50) cents a share.

The
options and option price will be fully vested in consideration for work
provided as described in this section. Work includes counseling on the message
strategy that will most likely result in media coverage, media outreach, press
release writing, alliance building with key stakeholders who can advocate on
behalf of Client, and other traditional PR activities.  

 

(b) This agreement is subject to review after 12 months, and
may be revised in accordance with both Agency's profit objective and Client's
program requirements upon mutual agreement of the parties.

 

(c) Large, specific projects like create a brochure or
development of a new Website require a “work order.”  The work order protects
both parties by agreeing to specific costs in advance, and require signatures
from Agency and Client.  Unless otherwise noted on a Client signed work order,”
monthly invoices for work completed will be rendered within 5 days of the last
day of each month and will be due and payable on receipt, and no more than 30
days from when they were received by Client. All approved work orders will be
paid in cash or an agreed upon financial transfer, Section (2d and 3) of this
agreement will be paid accordingly as well.

 

 

 

(d) Postage, express mail and other charges in the shipping
of copy, orders, prints and other materials to the Client, faxes to the Client,
on-line and telephone charges to the Client, traveling to or on behalf of the
Client, Web site and video production, and duplicating for Client, will be
billed at net cost to Client.  Client may be billed directly by Agency
vendors for approved expenses greater than US$1,000.  This payment
arrangement, and prompt payment of Agency invoices (within 30 days), alleviates
any Agency need to “mark-up” out of pocket expenses.  

 

3.   Client reserves the right to cancel or reject the plans
or schedules after they have been approved by the client, but, in that event,
agrees to reimburse Agency for reasonable expenses incurred in the preparation
of the cancelled project.  Client indemnifies and holds Agency harmless for all
costs and expenses related to cancelled projects that have been previously
approved by Client.

 

4.   Any invoice that remains unpaid for a period of 30 days
from the date Client receives Agency's invoice shall be subject to an interest
charge of 1.5 % per month until the invoice is paid in full.  The interest rate
shall continue to accrue on the unpaid balance following any judgment that may
be entered in favor of Agency.

 

5. Client shall pay agency per section 2 of this
agreement. If at any time this contract is terminated by either party,
the remaining funds not already expended by the Agency at the time of
notification of cancellation by the Client shall be returned to Client.

 

6.   (a)  Client shall indemnify, defend and hold harmless
Agency from any damages, claims, costs and expenses (including attorney's fees)
asserted against Agency arising from Client's breach of this Agreement or from
any advertising, public relations or promotional materials, or commercial data
or materials, furnished to Agency by Client or from the negligent or willful
acts of Client.  This indemnification shall extend to all claims including the
claims resulting from the use or consumption of Client's products in market
testing or in general public usage.  Notwithstanding the foregoing, Agency
reserves the right to participate in the defense of any claim with its own
counsel, at Agency's sole cost and expense.  This indemnification shall not
cover punitive, consequential or incidental damages, including, without
limitation, loss of profits other than loss of profits relating to this
Agreement.

 

(b) Agency shall indemnify, defend and hold harmless Client
from any damages, claims, costs and expenses (including attorneys' fees)
asserted against Client arising from Agency's breach of this Agreement or from
any advertising, public relations or promotional materials, or commercial data
or materials, furnished to Client by to Agency or from the negligent or willful
acts of Agency.  Notwithstanding the foregoing, Client reserves the right to
participate in the defense of any claim with its own counsel, and at Client's
sole cost and expense.  This indemnification shall not cover punitive,
consequential or incidental damages, including, without limitation, loss of
profits other than loss of profits relating to this Agreement.

 

 

 

 

 

7.   This Agreement shall continue until terminated by
either party upon sixty (60) days' prior written notice, and during that sixty
day period, the rights, duties and responsibilities of Agency, and the
obligations of Client, shall continue in full force and effect except that upon
a breach of this Agreement, the other party may terminate immediately upon written
notice to the breaching party.  Upon termination, Client agrees to compensate
Agency for work performed and expenses incurred prior to the date of
termination.

 

8.   This Agreement shall be construed in accordance with
the laws of the District of Columbia, U.S., without regard to the law of
conflicts of law and without regard to any rule of interpretation relating to
which party drafted this Agreement.

 

9.   All disputes arising out of or relating to this
Agreement shall be decided by arbitration in Washington, DC, in accordance with
the Rules of the American Arbitration Association then obtaining unless the
parties mutually agree otherwise.  This agreement to arbitrate shall be
specifically enforceable under the prevailing arbitration law.  The award rendered
by the arbitrator shall be final and judgment may be entered in accordance with
applicable law in any court having jurisdiction.  Notice of the demand for
arbitration shall be filed in writing with the other party to this Agreement
and with the American Arbitration Association.  The demand for arbitration
shall be made within two (2) years after the dispute in question has arisen. 
If any action is necessary to enforce any of the terms of this Agreement, the
prevailing party shall be entitled to receive from the other party all costs
and fees, including reasonable attorneys' fees, and interest at the rate set
forth in this Agreement.

 

10. This Agreement constitutes the entire understanding
between the parties superseding all previous agreements, representations and
warranties regarding the subject matter, whether oral or written, and this
Agreement can only be amended in writing signed by both parties.  No statement
was made by any party to induce the other party to enter into this Agreement, which
is not set forth in this Agreement.

 

11. This Agreement may be executed in counterparts, each of
which shall be deemed an original but all of which taken together shall
constitute one agreement.  A facsimile copy of a signature on this Agreement
may serve as an original.

 

12. The parties agree to use their best efforts, and act in
good faith, in performance of their obligations under this Agreement, and to
take any and all steps as are necessary to fulfill their obligations under this
Agreement.

 

 

 

 

 

 

 

 

 

 

 

 

13. If any provision of this Agreement is determined by a
court of competent jurisdiction to be unenforceable or invalid, the provision
shall be modified to the extent necessary to make it valid and enforceable and
to the extent of any remaining unenforceability or invalidity shall have no
effect on the remaining provisions of this Agreement.

 

CLIENT:                                                                                  AGENCY:

 

 

 

 

By:                   ___________                                                  By: ________________________

 

Ara Ghanime                                                                            David
H. Sheon

Immunotech Laboratories, Inc.                                                 WHITECOAT
Strategies, LLC

 

July 6, 2009                                                                             July
6, 2009

 

 

 

 

By:                   ___________  

 

Harry Zhabilov

Immunotech Laboratories, Inc.

 

July 6, 2009

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]